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Abstract: Isoliquiritigenin (ISL), a natural anti-breast cancer dietary compound, has poor 
delivery characteristics and low bioavailability. In order to promote the therapeutic outcome 
of ISL, a tumor-targeting lipid–polymer hybrid nanoparticle (NP) system modified by tumor-
homing iRGD peptides has been developed. The hybrid NPs were prepared by a modified 
single-step nanoprecipitation method to encapsulate ISL. iRGD peptides were anchored on 
the surface by a postinsertion method (ISL-iRGD NPs). The stable lipid–polymer structure of 
ISL-iRGD NPs, with high encapsulation and loading efficiency, was confirmed. Compared to 
free ISL and non-iRGD-modified counterparts, ISL-iRGD NPs showed higher cytotoxicity and 
cell apoptosis against the different type of breast cancer cells. This was attributable to higher 
cellular accumulation mediated by the iRGD-integrin recognition and the nanoscale effect. 
More importantly, based on the active tumor-tissue accumulation by iRGD peptides and the 
prolonged in vivo circulation by the stealth nanostructure, ISL-iRGD NPs displayed higher 
tumor-growth inhibition efficiency in 4T1-bearing breast-tumor mouse models. Therefore, the 
constructed iRGD modified lipid–polymer hybrid NPs would provide a promising drug-delivery 
strategy to improve ISL in anti-breast cancer efficacy.
Keywords: isoliquiritigenin, iRGD, lipid–polymer hybrid NPs, breast cancer
Introduction
The morbidity of breast cancer has ranked first in female cancers for a long time 
worldwide. In some developed regions, breast cancer is still the second-commonest 
major cause of cancer death.1,2 Currently chemotherapy remains the irreplaceable 
method in treating breast cancer in clinic, yet it has limited efficacy and can produce 
some serious side effects for patients.3–6 On the other hand, seeking natural compounds 
in treating breast cancer has become a promising research area and attracted a lot 
of scholars, due to some compounds’ high efficacy and minor side effects, such as 
curcumin, (-)-epigallocatechin gallate, and emodin.7 In very recent years, we have 
found a flavonoid, isoliquiritigenin (ISL; structure in Figure 1A), that is not only 
able to inhibit angiogenesis of breast cancer cells via the VEGF–VEGFR2 pathway8 
and prevent mammary carcinogenesis through WIF1 demethylation,9 but can also 
chemosensitize breast cancer stem cells,10 serving as an autophagy inducer regulating 
chemoresistance-associated autophagy.11 In addition, studies have shown that ISL can 
treat breast cancer via NFκB signaling and the PI3K–Akt pathway, inhibiting p38 
expression and downregulating AA-metabolizing enzymes.12–14 This evidence has 
demonstrated that ISL can be a promising anti-breast cancer agent worthy of being 
Correspondence: Jianping Chen
School of Chinese Medicine, Li Ka Shing 
Faculty of Medicine, University of Hong 
Kong, 10 Sassoon Road, Pokfulam, 
Hong Kong 999077
Tel +852 9514 7068
Fax +852 2872 5476
email abchen@hku.hk 
Journal name: International Journal of Nanomedicine
Article Designation: Original Research
Year: 2017
Volume: 12
Running head verso: Gao et al
Running head recto: ISL-loaded iRGD NPs in breast cancer
DOI: http://dx.doi.org/10.2147/IJN.S134148
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f N
an
om
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
7.
8.
23
0.
57
 o
n 
31
-A
ug
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of Nanomedicine 2017:12submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
4148
gao et al
developed. However, currently its use in clinical application 
is limited by several factors, such as poor solubility, low 
bioavailability, high effective dose (50 mg/kg mouse body 
weight), and poor targeting ability (very low concentra-
tions in mammary tissue).9,15 Therefore, dealing with these 
problems is a key process in its development.
Nanoparticles (NPs) are a typical nanodelivery system 
that can improve solubility, enhance bioavailability, and 
increase targeting distribution of a drug,16 while lipid–
polymer NPs represent a promising delivery platform that 
combines the biomimetic advantages of liposomes and 
mechanical advantages of biodegradable polymeric NPs.17,18 
In addition, modification of targeting peptides on the surface 
of the NPs serves as a smart design for enhancing targeting 
distribution.19 iRGD peptides, nine-unit cyclic (CRGDK/
RGPD/EC) tumor-homing peptides with an RGD sequence 
were selected, since they bind preferentially to integrin α
v
β
3
 
receptors, α
v
β
5
 integrin receptors and Nrp1 receptors. Firstly, 
the iRGD peptide can directly bind to αβ integrin, which is 
overexpressed on the surface of cancer cells and tumor-vessel 
cells but not in normal vessel cells, and then proteolytically 
turns into CRGDK/R, exposing an active CendR motif at 
the C-terminus. Finally, the CendR motif binds with the 
permeability-regulating receptor Nrp1 in cancer cells.20–23 
Therefore, modified iRGD peptides on the surface of 
lipid–polymer NPs represent an effective design.
To the best of our knowledge, recent attempts to improve 
ISL delivery via nanosystems against cancer have been very 
limited and the outcomes not very satisfactory, ie, in the form 
of nanomaterial toxicity and poor targeting ability of existent 
NPs.24,25 Herein, iRGD-modified lipid–polymer NPs were 
used to encapsulate ISL (structure of NPs in Figure 1A). The 
basic characteristics, pharmacological efficacy, and targeting 
ability of the novel NPs were studied and are evaluated in 
this paper.
Materials and methods
Materials and reagents
The animal experiments were approved by the ethics 
committee of the University of Hong Kong (HKU, permit 
3684-15), and we followed the animal-welfare guidelines 
and basic regulations of Laboratory Animal Unit in HKU. 
ISL (purity .97%) was bought from Thermo Fisher 
Scientific (Waltham, MA, US). 1,2-Distearoyl-sn-glycero-
3-phosphoethanolamine-N-(maleimide[polyethylene 
glycol]
2,000
) (DSPE-PEG
2,000
-Mal) was purchased from 
Laysan Bio (Arab, AL, US). Poly(lactic-co-glycolic acid) 
(PLGA)-COOH (intrinsic viscosity [dL/g] 0.08, molecular 
,6/L5*'13V,6/13V)UHH,6/
6HGLPHQW
,VROLTXLULWLJHQLQ
3/*$
+2 2+
2+ 2
L5*'
'63(3(*0DO
6R\EHDQOHFLWKLQ
%
$
Figure 1 Image and structure of ISL-iRGD NPs and ISL.
Notes: Schematic representation of ISL-iRGD NPs (A); photographic image of different drugs (free ISL, ISL NPs and ISL-iRGD NPs) in aqueous solution (B).
Abbreviations: ISL, isoliquiritigenin; NPs, nanoparticles; PLGA, poly(lactic-co-glycolic acid); DSPE, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine; PEG, polyethylene 
glycol; Mal, maleimide.
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weight 5,000 Da) was obtained from Dalian Biotechnology 
(Nanjing, China). Lecithin was bought from Solarbio 
Science and Technology (Beijing, China). Coumarin 6 (C
6
; 
laser grade) was obtained from Aladdin Reagent (Shanghai, 
China). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide (MTT) and Hoechst 33342 were purchased 
from Thermo Fisher Scientific. A fluorescein isothiocyanate 
(FITC)–annexin V apoptosis-detection kit used to investigate 
apoptosis activity was obtained from BD Biosciences (San 
Jose, CA, US). All reagent water was pretreated with the 
Milli-Q Plus system (EMD Millipore, Billerica, MA, US). 
All solvents, including dimethyl sulfoxide (DMSO), ethanol, 
acetonitrile, and methanol, were of chromatographic grade 
and used without further treatment.
Preparation of Isl-irgD NPs
ISL-iRGD lipid–polymer NPs composed of a polymeric 
PLGA core coated with a layer of lipids and a PEG layer 
were prepared by modified single-step nanoprecipitation, 
based on a previous study.26 In brief, DSPE-PEG-Mal (6 
mg) and lecithin (4 mg) solution were dissolved in 0.5 mL 
alcohol and then added to 9 mL water. The DSPE-PEG–
lecithin solution was stirred and heated to 65°C, to ensure 
all lipid was in liquid phase. Additionally, 1.2 mg of ISL 
and 10 mg of PLGA was dissolved in 0.5 mL of alcohol and 
acetonitrile, respectively. The PLGA solution mixed with ISL 
was then added to a prepared liquid-lipid solution dropwise 
under stirring at 700 rpm for 6 hours at room temperature. 
The remaining organic solvent was evaporated in a vacuum, 
and the nanosuspension was filtered with a 0.45 μm filter to 
remove free molecules. Finally, iRGD peptides were modi-
fied on the surface of NPs by a postinsertion approach based 
on the mild conjugation between the Mal group on the PEG 
layer and the terminal sulfhydryl group of iRGD. iRGD 
(1 mg) was added to the ISL-loaded NP suspension for 30 
minutes’ shaking at room temperature.
Physical property characterization
The objective of studying property characterization was to 
evaluate the general physical properties and basic structures 
of the NPs, as well as to discover evidence to confirm whether 
the drugs were loaded into the NPs or not. NPs were charac-
terized by particle size, ζ-potential, X-ray diffraction, infra-
red radiation, differential scanning calorimetry (DSC), and 
transmission electron microscopy (TEM). Particle size and 
ζ-potential were both detected by dynamic light scattering 
(Malvern Instruments, Malvern, UK) at 25°C. The morphol-
ogy of NPs was detected by TEM (Tecnai G20; Thermo 
Fisher Scientific) at operation voltage of 200 kV. Fourier-
transform infrared spectra (Nicolet iS 50; Thermo Fisher 
Scientific) were employed to characterize the encapsulation 
of ISL in NPs. Thermodynamic properties of ISL-iRGD NPs 
were detected by diamond DSC (PerkinElmer, Waltham, 
MA, US). The crystallographic structures of NPs were 
characterized by X-ray diffraction (Bruker Optik GmbH, 
Ettlingen, Germany).
EE, LE, and stability analysis
Loading efficiency (LE) and encapsulation efficiency (EE) 
of ISL were determined with high-performance liquid-
chromatography (HPLC) (Dionex Ultimate 3000; Thermo 
Fisher Scientific) equipped with a C
18
 column (250×4.6 mm). 
The mobile phase was methanol/water (70/30, v/v) with a 
detection wavelength of 306 nm. The flow rate was 1 mL/min. 
Methanol was used to disrupt the structure of NPs and dis-
solved ISL before it was analyzed by HPLC. Calculations 
of EE and LE were as follows:
 
EE 
Amount of ISL loaded
Amount of ISL added
(%) %= ×100
 
(1)
 
LE 
Amount of ISL loaded
Amount of ISL added polymer
(%) %=
+
×100
 
(2)
In addition, change in particle size, ζ-potential, EE, and 
LE for 15 days during storage at 25°C was carried out as the 
stability evaluation.
cell culture
Human breast cancer cell lines (MDA-MB231 and MCF7) 
and a mouse breast cancer cell line (4T1) were obtained from 
the American Type Culture Collection (Manassas, VA, US). 
Cells were cultured in medium (Dulbecco’s Modified Eagle’s 
Medium for MDA-MB231 and 4T1, Roswell Park Memorial 
Institute 1640 for MCF7) supplemented with 10% fetal bovine 
serum (Thermo Fisher Scientific) and 1% streptomycin and 
penicillin (Thermo Fisher Scientific). For all the in vitro 
experiments, free ISL was dissolved in DMSO in advance, 
and then diluted over 1,000-fold. All of the NPs or drugs were 
diluted by uncompleted medium (supplemented with 0.5% 
fetal bovine serum and 1% streptomycin and penicillin).
Cell-proliferation assays
MTT assay was used to evaluate the cell proliferation activity 
of different breast cancer cells. In brief, MDA-MB231, 4T1, 
and MCF7 cells were seeded onto the 96-well plates at a 
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density of 4×103 cells per well. Four groups (ISL-iRGD NPs, 
ISL NPs, free ISL, and blank NPs) were added to the wells 
with six duplicates for each concentration. After incubation 
for 24 hours, 20 μL MTT solution (5 mg/mL) was added into 
each well for 4 hours’ incubation. The MTT-added solution 
was then removed following the addition of 100 μL of DMSO 
to each well and mixed thoroughly with pipette. Afterward, 
the samples were incubated at 37°C for 10 minutes and 
mixed. Absorbance was read at 540 nm.
Apoptosis assays
The FITC–annexin V apoptosis-detection kit was used 
to determine the effects of cancer-cell apoptosis. MDA-
MB231 breast cancer cells were treated with the four drug 
groups (ISL-iRGD NPs, ISL NPs, free ISL, and blank 
NPs) with ISL concentration of 50 μM for 16 hours. Both 
nonadherent and adherent cells were collected. Pretreatment 
procedures were carried out as per the instructions of the 
FITC–annexin V apoptosis-detection kit. Cells were analyzed 
with an LSR Fortessa analyzer (BD Biosciences) within 1 hour. 
Annexin V–FITC+/PI- cells were considered early apoptotic 
cells, and annexin V–FITC+/PI+ cells were considered late 
apoptotic cells.
Cell-uptake analysis
Cellular uptake is an important index to estimate drug 
capacity to enter cells and drug concentration in cells.27 C
6
, a 
hydrophobic fluorescent dye, was used to label the NPs, and 
used to investigate the cell-uptake ability of different NPs 
qualitatively and quantitatively.28 The preparation method 
for encapsulating C
6
 was similar to ISL NPs.
Flow cytometry (FCM) was used for quantitative studies 
of the cellular uptake of NPs.29,30 MDA-MB231 breast 
cancer cells (8×105) were seeded onto the six-well plates. 
After 12 hours’ incubation, the medium was removed and 
the different drug solutions added at certain concentrations 
of C
6
. For the quantitative study, cells were incubated with 
C
6
-iRGD NPs, C
6
 NPs, and free C
6
 with an equivalent con-
centration of C
6
 (25 ng/mL) for 4 hours at 37°C. For dose-
dependent study, different concentrations of C
6
 (25, 12.5, 
6.25, 3.125 ng/mL) were used for incubation with cells for 
4 hours at 37°C. Furthermore, cells were incubated with 
C
6
-iRGD NPs (25 ng/mL) at different time points (0.5, 1, 2, 
and 4 hours) for time-dependent study. For the energy-
dependent study, cells were incubated with C
6
-iRGD NPs 
(25 ng/mL) at different time points (0.5, 1, 2, and 4 hours) 
at 37°C and 4°C, respectively. Untreated cells were used 
as controls.
Cellular uptake of various ISL samples was observed by 
fluorescence microscopy. MDA-MB231 breast cancer cells 
(5×104) were seeded onto the six-well plates. After 24 hours’ 
incubation, the completed medium was removed and 
different drug solutions at a concentration of C
6
 (85 ng/mL) 
added. The control group was untreated cells. After 4 hours’ 
incubation, the drug solutions were removed and washed 
twice with cold phosphate-buffered saline (PBS), fixed with 
4% paraformaldehyde in PBS for 10 minutes, washed twice 
more with PBS, and then stained with Hoechst 33342. Intra-
cellular Hoechst 33342 and C
6
 were excited and observed by 
fluorescence microscopy.
In vivo antitumor efficacy
Primarily, 4-week-old female nude mice were used to set up 
the breast-tumor mouse models. 4T1 cells (4×105 per mouse) 
were injected into the mammary gland via subcutaneous 
inoculation. After the tumor volume had reached about 
100 mm3, mice were assigned to four groups randomly: 
ISL-iRGD NPs, ISL NPs, free ISL (25 mg/kg mouse body 
weight), and blank NPs. Formulations were administered 
to mice once every 2 days by intraperitoneal injection for 
20 days after disinfection. Mice in the control group were 
administered normal saline only. Tumor volumes and body 
weight of mice were recorded once every 2 days. The tumor 
volumes were calculated using the formula V = W2 × L/2. 
At the end of the experiment, mice were used anesthetic 
to death and collected tumors, livers, lungs, and kidneys. 
Hematoxylin and eosin (H&E) staining was used in studying 
the histological characteristics of the different tissues.
Biodistribution analysis
To visualize tumor accumulation of NPs in breast-tumor 
mouse models, Cy5, a near-infrared fluorescence probe, 
was used to label NPs based on the preparation method of 
ISL NPs. After injecting 4T1 breast cancer cells in the nude 
mice for 10 days, the mice were divided into Cy5-iRGD NPs, 
Cy5 NPs, and free Cy5 groups. Biodistribution analysis was 
conducted, described as follows. Firstly, mice were given 
Cy5 (35 μg/kg) via intravenous (IV) injection. Secondly, 
mice were imaged using an IVIS Spectrum (PerkinElmer) 
in vivo imaging system after injecting the Cy5 at four time 
points (2, 6, 12, and 24 hours). Finally, tumors, lungs, hearts, 
spleens, and kidneys were collected and imaged.
statistics
All data were presented as means ± standard deviation 
(SD). All experimental results were confirmed in at least 
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three independent experiments under the same conditions. 
Statistical comparison was carried out with Student’s t-test. 
P,0.05 was considered statistically significant.
Results and discussion
Preparation and characterization of 
Isl-irgD NPs
Based on the aforementioned procedures, ISL-loaded 
hybrid NPs composed of a polymeric PLGA core coated 
by a layer of lipids and PEG were prepared, and iRGD 
peptides were modified on the surface of NPs by postin-
sertion, with the structure shown in Figure 1A. With its 
significant improvement in water-solubility, the ISL-loaded 
NP suspension appeared as a homogeneous light-yellow 
solution, instead of lots of sediment in free ISL solution 
(Figure 1B).
The average size distribution of ISL-iRGD NPs was 
137.2±2.6 nm (relative SD 1.87%) and the ζ-potential 
-34.21±1.23 mV (relative SD 3.59%) (Figure 2A and B). As 
is well known, NPs with small particle size less than 200 nm 
can accumulate in tumor cells via the enhanced permeability 
and retention (EPR) effect. Also, NPs with high absolute 
negative ζ-potential suggests satisfactory stability, as well as 
avoidance of particle aggregation and protein adsorption in 
blood circulation. Therefore, these NPs would be expected to 
show good stability and drug accumulation in tumor-tissue. 
Morphologically, the TEM images of ISL-iRGD NPs and 
blank NPs showed that distribution was uniform and the 
shape round and smooth (Figure 2C and D), which also 
indicated the loading procedure of ISL had not influenced 
NP formation.
The infrared spectra of ISL-iRGD NPs and other for-
mulations were detected to confirm the structure of NPs. 
A strong peak at 1,228.494 cm-1 was detected only in the 
free ISL, mixed free ISL, and blank NPs, which indicated this 
peak was specific for ISL (Figure 2E). However, this peak 
disappeared from the ISL NPs, which means ISL was not 
detected on the surface of NPs and was loaded in the core. 
Moreover, the peaks of 2,921.771 cm-1, 2,854.272 cm-1, and 
1,758.849 cm-1 were detected in mixed free ISL, blank NPs, 
and ISL NPs, respectively, but not free ISL itself, which is 
supplementary evidence to confirm ISL loading in the core 
of the NPs. In DSC or X-ray spectrum evaluation (Figure 2F 
and G), the spectrum profile or specific peaks of blank NPs 
were similar to ISL NPs; the same conclusion as for infrared-
spectrum analysis. All the three spectra confirmed the same 
fact that ISL was encapsulated in the core of the NPs but 
not on the surface.
Drug-loading and -stability evaluation 
in vitro
The EE and LE of ISL-iRGD NPs in Milli-Q water were 
90.8%±1.5% and 4.13%±0.4%, respectively. The stability 
of ISL-iRGD NPs was tested for 15 days at 4°C. Results are 
shown in Table 1. The particle size of ISL-iRGD NPs changed 
from 138.97±2.44 (day 1) to 134.48±2.65 nm (day 15), but 
without significant difference (P.0.5). In addition, the other 
three indices – ζ-potential, EE, and LE – all showed slight 
changes from day 1 to day 15. These findings indicated ISL-
iRGD NPs were stable during the 15 days.
Cytotoxicity and apoptosis analysis of 
Isl-irgD NPs in vitro
To evaluate the anti-breast cancer effects of ISL-iRGD NPs 
in vitro, MTT and double-staining apoptosis assays were con-
ducted. Three typical breast cancer cell lines – MCF7, MDA-
MB231, and 4T1 – were used in the MTT assay. These cell 
lines were incubated with four different formulations (blank 
NPs, free ISL, ISL NPs, and ISL-iRGD NPs) for 24 hours. 
For blank NPs, there was no obvious cytotoxicity against any 
cell lines, which was also evidence to eliminate the influence 
caused of the nanomaterials. For MCF7, ISL-iRGD NPs had 
better inhibition effects than free ISL at high concentrations 
(.12.5 μM, P,0.05) but they were not better than ISL NPs 
(Figure 3A). For MDA-MB231 and 4T1, ISL-iRGD NPs 
had better inhibition effects than ISL NPs and free ISL at 
all concentrations (P,0.05), which means iRGD enhanced 
the efficacy of ISL NPs in cytotoxicity (Figure 3B and C). 
Moreover, this evidence indicates that MDA-MB231 and 4T1 
were more sensitive to the ISL-iRGD NPs than MCF7.
Based on the high sensitivity of MDA-MB231 to the 
ISL-iRGD NPs in cytotoxicity assays, MDA-MB231 was 
selected to evaluate the apoptosis-inducing efficacy of dif-
ferent formulations, and the results are shown in Figure 3D 
and Figure S1. After incubation for 16 hours, the apoptosis 
rate of free ISL and ISL NPs was similar (P.0.05), which 
indicated the nanoscale of ISL may not have contributed 
to the efficacy of inducing MDA-MB231-cell apoptosis. 
However, ISL-iRGD NPs presented higher rates of apoptosis 
(about 40%) than the other four groups, which suggested the 
stronger efficacy may have been caused by the tumor-homing 
iRGD peptides (P,0.05).
Cell-uptake ability of ISL-iRGD NPs
As previously mentioned, iRGD is a tumor-homing pep-
tide that shows positive targeting ability for cancer cells. 
Moreover, the average size of the ISL-iRGD NPs was about 
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f N
an
om
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
7.
8.
23
0.
57
 o
n 
31
-A
ug
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of Nanomedicine 2017:12submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
4152
gao et al
     










)UHH,6/
%ODQN13V
,6/13V
0L[HGIUHH,6/DQGEODQN13V
:DYHQXPEHUVFP±
(
  7HPSHUDWXUH°& θ°
)UHH,6/
%ODQN13V
,6/13V
0L[HGIUHH,6/DQGEODQN13V
  
)UHH,6/
%ODQN13V
,6/13V
0L[HGIUHH,6/DQGEODQN13V
) *
&
'
QP
%ODQN13V
QP
,6/13V$
%
±±±± ±  
7RWD
OFR
XQW
V
  
,QWH
QVLW
\

Figure 2 Characteristics of ISL-iRGD NPs.
Notes: Particle-size distribution (A), ζ-potential distribution (B), transmission electron microscopy (C [ISL-iRGD NPs], magnification ×200,000; D [blank NPs]; magnification 
×50,000), infrared radiation (E), differential scanning calorimetry (F), and X-ray diffraction (G) of different polymer drug-delivery systems and free drug.
Abbreviations: ISL, isoliquiritigenin; NPs, nanoparticles.
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137.2 nm, which is also a good size range for passive 
targeting of NPs. Therefore, two methods were used to evalu-
ate the cell-uptake ability of different formulas: fluorescence 
microscopy and FCM.
Fluorescence microscopy is a typical method for qualita-
tive analysis of cell-uptake ability of NPs. The intensity of 
the dye in the image can reflect the concentration of target-
drug uptake by certain cells indirectly. Figure 4A presents 
fluorescence-microscopy images of the different formulations 
taken up by MDA-MB231. The concentration of C
6
 in all 
formulas was 85 ng/mL. After incubating with the different 
C
6
 formulations for 4 hours, C
6
-iRGD NPs presented the 
greatest intensity and were most closely situated around 
nuclei compared to C
6
 NPs and free C
6
, which illustrated 
C
6
-iRGD NPs were prone to internalize in MDA-MB231 
cells and showed excellent targeting ability.
Qualitative analysis of the NPs was measured by FCM to 
confirm uptake efficacy and evaluate the manner of uptake 
of C
6
-iRGD NPs. As shown in Figure 4B, after incubation 
of MDA-MB231 with different C
6
 formulations (C
6
-iRGD 
NPs, C
6
 NPs, and free C
6
) for 4 hours, the FCM-detection 
profiles and histogram results of mean fluorescence intensity 
showed the intensity of C
6
 in C
6
-iRGD NPs was strongest 
(P,0.05), followed by C
6
 NPs and free ISL. This confirmed 
the results of fluorescence microscopy, and also illustrated 
the strong cell-uptake ability of ISL-iRGD NPs. Moreover, 
it also indicated that the high uptake capacity of the system 
may have been due to its nanoscale and the iRGD peptide.
The manner of uptake of C
6
-iRGD NPs was also detected 
by FCM. The FCM profile and histogram both showed the 
mean intensity of C
6
 increased with ISL dosage (Figure 4C) 
or time (Figure 4D and Figure S2), which indicated that 
the cell-uptake efficacy in MDA-MB231 of C
6
-iRGD NPs 
Figure 3 In vitro cytotoxicity and apoptosis analysis of ISL-iRGD NPs.
Notes: Cell viability of MCF7 (A), MDA-MB231 (B), and 4T1 (C) breast cancer cell lines after incubation with ISL-iRGD NPs, ISL NPs, blank NPs and free ISL for 24 hours. 
Apoptosis analysis of MDA-MB231 after treated by ISL-iRGD NPs, ISL NPs, blank NPs and free ISL (D). *P,0.05 vs free Isl; P,0.05 vs Isl NPs.
Abbreviations: ISL, isoliquiritigenin; NPs, nanoparticles.
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Table 1 Stability of ISL-iRGD lipid–polymer NPs over 15 days
Particle size ζ-Potential EE LE
Day 1 138.97±2.44 -36.15±0.74 90.4%±1.8% 4.06%±0.38%
Day 15 134.48±2.65 -31.91±1.98 87.1%±1.2% 3.91%±0.4%
Note: all data were presented as mean ± standard deviation. 
Abbreviations: ISL, isoliquiritigenin; NPs, nanoparticles; EE, encapsulation efficiency; 
LE, loading efficiency.
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f N
an
om
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
7.
8.
23
0.
57
 o
n 
31
-A
ug
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of Nanomedicine 2017:12submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
4154
gao et al
Figure 4 Cell-uptake evaluation of different C6 formulations using the MDA-MB231 cell line.
Notes: (A) Fluorescent images of MDA-MB231 cells incubated with different C6 formulations (C6-irgD NPs, c6 NPs, and free c6) for 4 hours; magnification ×200. c6 
incubation concentration was 85 ng/mL. (B) Quantitative measure of C6 uptake in different C6 formulations (C6-irgD NPs, c6 NPs, and free c6) after incubation for 4 hours. 
c6-incubation concentration was 25 ng/mL. *P,0.05 vs free c6; 
P,0.05 vs c6 NPs. (C) Quantitative measure of C6 uptake in C6-iRGD NPs at different dosages (25 ng/mL, 
12.5 ng/mL, 6.25 ng/mL, and 3.125 ng/mL) after incubation for 4 hours. (D) Quantitative measure of C6 uptake in C6-iRGD NPs at different incubation time points (0.5, 1, 2, 
and 4 hours). C6 concentration was 25 ng/mL. (E) Mean fluorescence intensity versus time profile after incubation with C6-irgD NPs at 4°c and 37°C for 4 hours.
Abbreviations: ISL, isoliquiritigenin; NPs, nanoparticles.
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occurred in a dosage-dependent or time-dependent manner, 
respectively. Further analysis demonstrated that the inten-
sity of C
6
 at 37°C is stronger than at 4°C at all time points 
(Figure 4E), and intensity increased obviously with time at 
37°C but not at 4°C, which suggested uptake behavior relied 
mainly on endocytosis, rather than physical adsorption or 
passive diffusion. In other words, cell uptake was energy-
dependent.30 This cell-uptake ability indicated that the iRGD 
peptide can enhance the cell-uptake efficacy of C
6
-iRGD NPs 
in time-dependent, dosage-dependent, and energy-dependent 
manners, which is the main reason for the excellent efficacy 
of ISL-iRGD NPs in anti-breast cancer, rather than ISL-NPs 
or free ISL.
In vivo antitumor efficacy of 
Isl-irgD NPs
Based on the strong sensitivity of the 4T1 cell line on ISL-
iRGD NPs, the classic 4T1-bearing nude-mouse model was 
selected to evaluate the in vivo anticancer efficacy of different 
formulations. Images of the tumors of the different groups are 
shown in Figure 5A. Further analysis comparing mean tumor 
volume between the ISL-iRGD NPs and the other three groups 
(free ISL, blank NPs, and control) showed significant differ-
ence (P,0.05) was observed from the 14th day (Figure 5B). 
For the end point, the mean tumor volume of ISL-iRGD NPs 
decreased to about 474 mm3 compared to the other three 
groups (Figure S3). In addition, the mean tumor-volume 
burden also confirmed a similar outcome with mean tumor-
volume analysis. The mean tumor burden in ISL-iRGD NPs 
was lower then for free ISL, blank NPs, and the control group 
(P,0.05), and slightly lower than the ISL NPs (Figure 5C). 
These results and the graphs indicate that ISL-iRGD NPs 
showed better anti-breast cancer efficacy than the other four 
groups (ISL NPs, free ISL, blank NPs, and control).
Furthermore, H&E staining was used to record mor-
phology changes among the different groups (Figure 5E). 
The quantity of mitotic-bodies in ISL-iRGD NPs and ISL 
NPs was higher than the other three groups, suggesting the 
viability of tumor cells was inhibited in ISL-iRGD NPs 
and ISL NPs in vivo. However, the blank NPs had similar 
morphology to the controls, which confirmed the low/absent 
anti-breast cancer effects of the nanomaterials.
For assessment of toxicity of the different formulas, body 
weight and H&E staining of organs were used. Body weight 
varying with time was recorded for 20 days, and there was 
no significant difference among the five groups (Figure 5D), 
which showed these five formulae had no obvious side 
effects on the animals. On the other hand, H&E staining of 
lungs, livers, and kidneys is shown in Figure S4. For lungs, 
all of the groups had lung metastasis detected, which met 
the basic characteristics of the 4T1-bearing mice model. For 
livers and kidneys, there were no remarkable morphological 
changes observed among the groups. All in all, this evidence 
confirmed the fact that our NPs had no obvious toxicity to 
the mice in this research.
As for dosage, 50 mg/kg/day was an effective dose 
for free ISL in nude mice in our preliminary studies.24,31–33 
However, in this project the effective dose was decreased to 
25 mg/kg every 2 days in the 4T1-bearing nude-mouse model. 
Also, the administration method was intraperitoneal rather 
than IV injection, which was because the volume of the NPs 
was too large to use IV injections. In sum, ISL-iRGD NPs 
had excellent ability for anti-breast cancer targeting in vivo 
with relative nontoxicity.
Biodistribution characteristics of 
Isl-irgD NPs
In vitro targeting ability of ISL-iRGD NPs was evaluated 
by fluorescence microscopy and FCM in the foregoing 
sections, with satisfactory results, meeting our expectations. 
However, these findings focused only on manner of uptake 
at the cellular level. For passive uptake of NPs caused by 
the EPR effect, only in vivo research can be used. Moreover, 
in vivo biodistribution evaluation can show the targeting 
ability of ISL-iRGD NPs objectively and directly. Therefore, 
the in vivo biodistribution characteristics of ISL-iRGD 
analysis were assessed using the IVIS Spectrum in vivo 
imaging system.
Figure 6 shows the results of the biodistribution analysis 
of ISL-iRGD NPs. After IV injection of free Cy5, it was 
observed that the Cy5 accumulated mainly in the liver and 
intensity decreased at a higher speed than in the other two 
groups during the 24 hours. Moreover, little fluorescence 
was detected in tumors at 12 and 24 hours. However, in 
Cy5-iRGD NPs, fluorescence was detected at all four time 
points with relatively high intensity. Compared with Cy5 
NPs, the detectable fluorescence area in tumors of Cy5-iRGD 
NPs was larger. The fluorescence signals of different organs 
or tissues in each group showed that the intensity of Cy5 in 
tumors followed an ascending order: Free Cy5, Cy5 NPs, 
and Cy5-iRGD NPs (P,0.05). In addition, Cy5 was mainly 
accumulated in the liver with stronger intensity compared to 
the other two groups (P,0.05). All in all, based on biodis-
tribution analysis in vivo, Cy5-iRGD NPs showed better 
tumor-targeting ability than free Cy5 and Cy5 NPs, perhaps 
due to the tumor-homing iRGD peptide and EPR effect.
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Figure 5 In vivo antitumor efficacy of ISL-iRGD NPs, ISL NPs, free ISL, blank NPs, and saline in the tumor-bearing mouse model.
Notes: (A) Graph of the tumor after intraperitoneal injection of different ISL formulations (25 mg/kg); (B) profile of mean tumor volume varying with time among different 
groups (*P,0.05 vs free ISL, blank NPs, and saline); (C) mean tumor burden among different ISL formulations (*P,0.05); (D) profile of the mean mouse body weight varying 
with time among different groups; (E) H&E staining on tumor (×20 objective). The red arrows indicate the mitotic-bodies of the cancer cells.
Abbreviations: ISL, isoliquiritigenin; NPs, nanoparticles; H&E, hematoxylin and eosin.
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Figure 6 Biodistribution analysis of free Cy5, Cy5 NPs, and Cy5-iRGD NPs in the tumor-bearing mouse model.
Notes: Mice were injected intravenously via the tail vein with free Cy5, Cy5 NPs, and Cy5-iRGD NPs (35 μg/kg mice). (A) Fluorescence images of mice treated with different 
Cy5 formulations in vivo at different time points (2, 6, 12, and 24 hours). (B) Fluorescence images of mice organs treated with different Cy5 formulations for 24 hours in vivo 
and fluorescent-signal analysis of different organs/tissues in each group. *P,0.05 compared with free Cy5; P,0.05 compared with Cy5 NPs.
Abbreviations: ISL, isoliquiritigenin; NPs, nanoparticles.
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Conclusion
In this study, ISL-iRGD NPs were prepared successfully. 
The size of the NPs was about 130 nm, which is the appropri-
ate size for the EPR effect in cancer therapy.28 The ζ-potential 
of ISL-iRGD NPs was about -34 mV, which indicated a 
relatively stable system.29 ISL-iRGD NP structure was also 
confirmed by four different methods, which demonstrated 
that the ISL was successfully encapsulated in the core of the 
NPs with high stability. In addition, they also had sufficient 
entrapment efficiency and loading efficiency. Compared with 
ISL NPs and free NPs, ISL-iRGD NPs had better efficacy 
in anti-breast cancer targeting and stronger targeting ability. 
In the pharmacodynamic study in vitro, ISL-iRGD NPs 
showed stronger inhibition effects and induced apoptosis 
effects. In the in vivo research, ISL-iRGD NPs showed stron-
ger effects in inhibiting tumor growth and viability of tumor 
cells. The toxicity of the nanomaterials was also evaluated. 
The in vivo study outcome showed the nanomaterials had no 
significant damaging effects on normal tissue. The targeting 
ability of ISL-iRGD NPs was detected in vivo and in vitro. 
The data showed that ISL-iRGD NPs had better ability in 
increasing cell-uptake efficiency in a time-independent, 
dose-independent, and energy-independent manner. The 
biodistribution test also indicated that ISL-iRGD NPs were 
easier to target and accumulate in breast tumors. All in all, 
this new delivery system for encapsulating ISL was effective 
and can promote the development of ISL in breast cancer 
therapy in clinical practice.
The global burden of cancer has been increasing in 
the past few decades, raising the prospect of significant 
investment in health systems and thus posing a real medical 
problem. According to GloboCan data in 2012, breast 
cancer is the commonest cancer in women worldwide. Due 
to the serious toxicity of first-line synthetic agents, the high 
incidence of breast cancer and its correlation with cancer-
related deaths worldwide have prompted more attention 
on discovering novel and effective alternatives with fewer 
side effects. Natural products, such as dietary phytochemi-
cals, tea polyphenols, and resveratrol, are well recognized 
as effective agents in several human ailments, including 
cancer. A natural flavonoid, ISL has previously been 
demonstrated to exhibit antioxidant, anti-inflammatory, 
and tumor-suppression effects by inducing apoptosis, 
autophagy, and cell-growth inhibition. Nevertheless, the 
high lipophilicity and insufficient anticancer efficacy 
in comparison with synthetic agents like doxorubicin 
greatly limit its clinical efficacy. Recently, nanoscale 
carriers have played a significant role in drug delivery. 
Various types of nanovehicles, such as liposomes, micelles, 
and nanocapsules, can encapsulate poorly soluble drugs 
to improve solubility. More importantly, anticancer drugs 
loaded in NPs can easily permeate into the leaky vasculature 
of tumor-tissue and control the drug-release behavior at 
the tumor site, which has been well described to enhance 
anticancer efficiency.
Lipid-related NPs, with liposomes as the classic type, and 
polymer-manufactured NPs, such as polymeric micelles and 
dendrimers, are the two dominant classes of nanoscale drug 
vehicles, with the increasing backing of approved drug prod-
ucts, clinical trials, and research experiments. Although many 
advantages of these nanocarriers have been demonstrated on 
occasion to improve solubility, body circulation, and selec-
tive tumor distribution, unfortunately both classes suffer 
limitations in terms of their physicochemical and biological 
properties. Specifically, most liposomes exhibit superior 
biocompatibility, biodegradability, and nonimmunogenic 
response, because natural lipids are analogs of biological 
membranes. However, liposomes display poor storage 
stability, and are easily cleared by the reticuloendothelial 
system. On the other hand, polymeric NPs have advantages 
in particle size, stability, and drug loading. Therefore, 
herein we employed lipid–polymer hybrid NPs constituted 
of PLGA, lecithin, and PEG to combine the advantages of 
lipid NPs and polymeric NPs. Moreover, iRGD peptides 
were grafted to DSPE-PEG
2,000
-Mal to obtain tumor-targeting 
by the conjugation of the thiol group of iRGD to the Mal 
group of PEG.30 Our research confirmed significant targeting 
ability and anti-breast cancer effects both in vivo and 
in vitro. How to synthesize such materials using simpler and 
cost-effective methods would be the key question, which 
requires addressing.
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Figure S1 Flow cytometry of different ISL formulations for apoptosis analysis in MDA-MB231 cell lines.
Notes: Top left (Q1), necrotic cells (annexin V–FITC-PI+); top right (Q2), late apoptotic cells (annexin V–FITC+PI+); bottom left (Q3), live cells (annexin V–FITC-PI-); bottom 
right (Q4), early apoptotic cells (annexin V–FITC+PI-).
Abbreviations: ISL, isoliquiritigenin; PI, propidium iodide; NPs, nanoparticles.
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Figure S2 Flow-cytometry profile of MDA-MB231 cell line incubated with C6-iRGD NPs at different incubation time points (0.5, 1, 2, and 4 hours) at 4°c and 37°c.
Abbreviation: NPs, nanoparticles.
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Figure S4 Hematoxylin and eosin staining on lung, liver, and kidney (10× objective).
Abbreviations: ISL, isoliquiritigenin; NPs, nanoparticles.
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Figure S3 Mean tumor volume differences among different groups (*P,0.05).
Abbreviations: ISL, isoliquiritigenin; NPs, nanoparticles.
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